Rick E Winningham serves as the Chief Executive Officer of THERAVANCE BIOPHARMA INC, a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. With a career spanning over three decades in the biopharmaceutical industry, Winningham has established himself as a seasoned executive with a proven track record of leadership and strategic vision. Prior to his current role, he served as the Chairman and CEO of Theravance, Inc., which he co-founded in 1997. Under his leadership, Theravance successfully developed and commercialized several respiratory medicines, including the blockbuster drug, Anoro Ellipta. Winningham's professional background is marked by his ability to drive growth and innovation within the biopharmaceutical sector. He has been instrumental in forging strategic partnerships and collaborations that have propelled THERAVANCE BIOPHARMA INC to the forefront of drug development. His achievements include overseeing the company's successful IPO in 2014 and navigating the complex landscape of drug development and regulatory approval. Winningham's leadership style emphasizes a patient-centric approach, ensuring that the company's efforts are aligned with the needs of those suffering from serious medical conditions. As CEO of THERAVANCE BIOPHARMA INC, Rick E Winningham plays a pivotal role in steering the company's strategic direction and operational execution. He is responsible for overseeing the development of the company's diverse pipeline, which includes treatments for respiratory diseases, bacterial infections, and central nervous system disorders. Winningham's commitment to innovation and excellence has fostered a culture of scientific rigor and collaboration within the organization. His vision for the future of THERAVANCE BIOPHARMA INC is centered on delivering transformative therapies that address unmet medical needs and improve patient outcomes worldwide.